Previous studies have indicated close correlation between the adrenocorticotropin (ACTH) -suppressing activity of corticosteroids and their effectiveness in inducing decreases in circulating eosinophils and increases in blood glucose. Heretofore, any structural modification of steroid which has resulted in altered potency with respect to one of these activities has resulted in equivalent alteration of potency with respect to the others (1, 2). The present study is concerned with three synthetic analogues of cortisol which exhibit dissociation of these properties when administered to human subjects. Chemically, all three compounds differ from cortisol (hydrocortisone) in that they lack hydroxyl groups at the carbon-21 position. Biologically, all three have been found to be effective ACTH-suppressing agents with little or no eosinopenic or hyperglycemic activity.
Previous studies have indicated close correlation between the adrenocorticotropin (ACTH) -suppressing activity of corticosteroids and their effectiveness in inducing decreases in circulating eosinophils and increases in blood glucose. Heretofore, any structural modification of steroid which has resulted in altered potency with respect to one of these activities has resulted in equivalent alteration of potency with respect to the others (1, 2) . The present study is concerned with three synthetic analogues of cortisol which exhibit dissociation of these properties when administered to human subjects. Chemically, all three compounds differ from cortisol (hydrocortisone) in that they lack hydroxyl groups at the carbon-21 position. Biologically, all three have been found to be effective ACTH-suppressing agents with little or no eosinopenic or hyperglycemic activity.
METHODS
The following steroids (with convenient abbreviations) were assayed in normal human subjects: 1) 9a-fluoro-11,8,17a-dihydroxy-A"'-pregnene -3,20-dione (21 -desoxy-AFF); 2) 9a-21-difluoro,lfl,17a-dihydroxy-A4-pregnene-3,20-dione (difluoro); 3) 6a-methyl-9a-fluoro-llp,17a-dihydroxy-A" '-pregnene-3,20-dione-21-mesylate (mesylate); and 4) 9a-fluoro-11,S,17a,21-trihydroxy-A"'-pregnene-3,20-dione (AFF). In each assay AFF served as a biological standard.
Assays of ACTH-suppressing potency. ACTH-suppressing potency was judged from percentage decreases in urinary 17-hydroxycorticosteroids which occurred in response to steroids administered orally every 6 hours for a total of 48 hours. Tests were carried out at weekly intervals with each of 4 subjects receiving graded doses of each compound on a random schedule. Daily urinary 17-hydroxycorticosteroids were determined by a modification of the method of Silber and Porter (3) . Com-pleteness of urine collection was checked by creatinine determinations performed by the method of Folin as described by Hawk, Oser, and Summerson (4).
Assays of eosinopenic potency. Circulating eosinophils were counted at 9 a.m., 1 p.m., and 4 p.m. Steroids were administered orally immediately after the 9 a.m. determination. The decrease in circulating eosinophils was calculated for each of the two later determinations and expressed as a percentage of the initial count. The mean of these two percentages was taken as the index of eosinopenic potency. At least 4 subjects received graded doses of each test substance. * Each "control" value indicates the eosinophil count immediately before treatment. Each "Rx" value represents the average of the eosinophil counts at 4 and 7 hours after treatment. Abbreviations as in Table I. of this laboratory that the hyperglycemic effect of a glucocorticoid is more readily demonstrable 1 hour after the rapid intravenous infusion of a glucose load than it is under fasting conditions. Consequently, in this study the 1 hour postinfusion blood glucose concentration was employed in calculating the hyperglycemic potencies of the various steroids.
RESULTS
Mean responses to graded doses of the various steroids are depicted graphically in Figure 1 . Individual responses in the ACTH-suppression assay are shown in Table I , in the eosinopenia assay in Table II , and in the hyperglycemia assay in Table  III. ACTH-suppression assays ( Figure 1 ; Table I) The standard, AFF, was progressively more effective in suppressing ACTH as dosage increased from 0.06 to 0.5 mg every 6 hours. At somewhat Eosinopenia assays (Figure 1 ; Tables II and IV) The standard, zFF, was progressively more effective in decreasing the number of circulating eosinophils as dosage was increased from 0.25 to 4.0 mg. In contrast, the carbon-21-modified steroids failed to cause significant depression of eosinophils in any dosage employed. Slight eosinopenic activity could not, however, be excluded by examination of the available data. Therefore, calculation of the admittedly equivocal eosinopenic potency was attempted. The '24 of parallelism between the dose response curves of the standard and unknown steroids was clearly not valid. For this reason the method of Cornfield (8) was employed in calculating eosinopenic potencies of the carbon-21-modified steroids relative to that of AFF. This method makes no assumption of parallelism and accepts, instead, the possibility that the relative potencies of two compounds may vary with dosage.
Thus, when 21-desoxy-AFF was tested at a dosage of 10 mg, its eosinopenic potency was 1/36 that of AFF, but when tested at a dosage of 320 mg, its potency was only 1/2,050 that of AFF.
Similarly, when difluoro was tested at a dosage of 10 mg, its eosinopenic potency was 1/296 that of AFF, but when tested at a dosage of 160 mg, its potency was only 1/2,170 that of AFF. When mesylate was tested at a dosage of 10 mg, its eosinopenic potency was 1/537 that of AFF, and when tested at a dosage of 160 mg, its potency was only 1/5,250 that of AFF. It thus appeared that the larger the dose of 21-carbon-modified steroid, the less was its eosinopenic potency relative to that of the standard compound, AFF. This diminution of ratio of potency with increasing dosage TAB Estimates of potency (relative to AFF) and dissociation may be more apparent than real. It is possible that the carbon-21-modified steroids are devoid of eosinopenic effect regardless of dosage. If this is true, then the true ratio of potency should be 0 at all dosage levels. Because of the inherent variability of the biological assay, however, it is never possible to say with certainty that a steroid is absolutely devoid of eosinopenic activity. It has been necessary to use increasingly large doses of the carbon-21-modified steroids, therefore, in order to establish conclusively that their eosinopenic potencies (relative to the standard) are virtually infinitesimal.
Hyperglycemia assays (Figure 1 ; Tables III and  V) The standard, AFF, was increasingly effective in impairing glucose tolerance as dosage of the steroid was increased from 1 to 3 mg. In contrast, the carbon-21-modified steroids failed to cause significant impairment of glucose tolerance in any dosage employed. Once again, however, a slight degree of hyperglycemic activity could not be excluded. Therefore, as in the case of eosino- Dissociation of ratios of potency ACTH-suppressing vs eosinopenic potencies (Table IV) . The estimate of the potency of 21-desoxy-AFF relative to AFF in the ACTH-suppression assay was 1/11. The estimate of the potency of 21-desoxy-AFF relative to AFF in the eosinopenia assay was 1/36 at the lowest dose and 1/2,050 at the highest dose. The disparity between estimates of potencies for the two types of assay we refer to as "dissociation" of corticoid properties. As a measure of the disparity we have used the ratio of the estimates, which we refer to as the "dissociation ratio." For example, at the 10 mg dose level, 1/11 -1/36 gives a dissociation ratio of 3.3. The dissociation ratio ranged from 3 at the 10 mg dose level to 181 at the 320 mg dose level. The 95%o fiducial limits 2 on the ratio were 0.8 to 13 at the 10 mg dose level, but at each of the 40, 80, 160, and 320 mg dose levels, the lower fiducial limits excluded unity.
At these last four dose levels, the probability that the ACTH-suppressing potency exceeded that of 2 Calculated from the antilog of the difference in log potency ± a multiple of the standard error of the difference in log potency. The multiple is obtained from Table V1 of Fisher and Yates (9) . For degrees of freedom not covered in that table, the multiple was obtained from an approximation given by Cochran and Cox (10 It is thus suggested that the 21-hydroxyl group may be a more important determinant in the mechanism through which steroids exert their eosinopenic and hyperglycemic effects than it is in the mechanism through which they exert their ACTH-suppressing effect.
SUMMARY
Although the ACTH-suppressing, eosinopenic, and hyperglycemic activities of corticosteroids have previously been considered to be inseparable, three synthetic cortisol analogues have been found to exhibit significant degrees of dissociation among these biological activities. These three compounds were 1) 9a-fluoro-1 lf8,17a-dihydroxy-A1' 4-pregnene-3,20-dione; 2) 9a,21-difluoro-11/8,17a-dihydroxy-A4-pregnene-3,20-dione; and 3) 6a-methyl-9a-fluoro-1 1,3,17-dihydroxy-Al 4-pregnene-3,20-dione-21-mesylate. When compared with 9a- fluoro-1 1,3,17a ,21-trihydroxy-z1" 4-pregnene-3,-20-dione as a biological standard, all three of the above steroids were found to be somewhat less effective as ACTH-suppressing agents, but almost totally ineffective as eosinopenic and hyperglycemic agents. The degree of dissociation of ACTHsuppressing activity from eosinopenic and hyperglycemic activities became greater as dosage was increased and was statistically significant at the higher dosage levels for each of the three steroids.
